Radiopharm Theranostics to Raise Up to US$13M in Offerings
Radiopharm Theranostics announced a series of capital raises, including a US$4.1 million registered direct offering of ADSs and concurrent private placement of warrants in the US. Additionally, the company secured firm commitments for an Australian private placement of A$6.7 million (US$4.7 million) and plans a Share Purchase Plan for up to A$6 million (US$4.2 million) for Australian and New Zealand shareholders. The total potential gross proceeds from these offerings could reach approximately US$13 million, which will be used to fund clinical studies, therapeutic programs, and strategic initiatives.
Key Highlights
- Secured US$4.1 million gross proceeds from a registered direct offering of 1,281,646 ADSs at US$3.16 per ADS.
- Issued unregistered warrants to purchase up to 1,281,646 ADSs at an exercise price of US$3.79 per ADS.
- Received firm commitments for A$6.7 million (US$4.7 million) in an Australian private placement.
- Plans a Share Purchase Plan for up to A$6 million (US$4.2 million) for Australian and NZ shareholders.
- Total potential gross proceeds from all offerings are approximately US$13 million.
- Funds will support RAD101 Phase 3 study, RAD 204 dose escalation, and other therapeutic programs.
- Shareholder approval for certain Australian issuances and warrants is expected around September 11, 2026.
Price Impact
More from RADX
Radiopharm Theranostics RAD101 Phase 3 Trial Set for 1Q27; RAD301 Data Positive
Radiopharm Theranostics Seeks Approval for $18.5M Capital Raise
Radiopharm Theranostics Reports Positive RAD 101 Phase 2b Results; Raises $12.5M
More in Corporate Action